Mineralys Therapeutics MLYS
$13.66 −$0.50 (-3.53%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $13.70 +0.29%
Open$13.81
Prev close$14.16
Day range$13.57 – $14.79
Volume1.35M
Market cap$1.21B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$60.09M-46.1% YoY
Net profit-$57.33M-55.2% YoY
Diluted EPS-$0.64-23.1% YoY
Free cash flow-$43.10M-49.3% YoY
Operating cash flow-$43.10M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-68.5%
Return on assets-60.2%
Return on invested capital-61.7%
Current ratio11.83
Liabilities / assets20.1%
Cash & investments$624.67M
Total debt$98.27M
Net cash (debt)$526.40M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $60.09M | $246.04M | $45.34M | $170.60M | $38.28M |
| Selling and Admin Expenses | $37.42M | $24.66M | $20.98M | $38.60M | $13.88M |
| -General & Admin Expense | $37.42M | $24.66M | $20.98M | $38.60M | $13.88M |
| Research & Development | $22.67M | $221.38M | $24.37M | $132.01M | $24.40M |
| Operating Profit | -$60.09M | -$246.04M | -$45.34M | -$170.60M | -$38.28M |
| Net Non-Operating Interest Income (Expense) | $2.76M | $4.96M | $6.00M | $15.95M | $6.05M |
| Non-Operating Interest Income | $5.95M | $4.96M | $6.00M | $15.95M | $6.05M |
| Non-Operating Interest Expense | $3.19M | – | – | – | – |
| Pretax Profit | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Net Profit | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Profit from Continuing Operations | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Net Income to Parent Company | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Net Income to Common Stockholders | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Basic EPS | -$0.64 | -$2.85 | -$0.47 | -$2.29 | -$0.40 |
| Diluted EPS | -$0.64 | -$2.85 | -$0.47 | -$2.29 | -$0.40 |
| Other Income (Expense) | – | $13,000.00 | $5,000.00 | – | – |
| Other Non-Operating Income (Expenses) | – | $13,000.00 | $5,000.00 | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $630.12M | $667.85M | $652.86M | $661.81M | $661.81M |
| Total Current Assets | $627.99M | $665.80M | $652.47M | $661.39M | $661.39M |
| Cash and Cash Equivalents & Short-Term Investments | $624.67M | $661.41M | $646.06M | $656.64M | $656.64M |
| -Cash and Cash Equivalents | $101.27M | $138.27M | $112.78M | $172.92M | $172.92M |
| -Short Term Investments | $523.40M | $523.14M | $533.28M | $483.71M | $483.71M |
| Other Current Assets | $3.32M | $4.39M | $6.41M | $4.75M | $4.75M |
| Total Non-Current Assets | $2.13M | $2.05M | $392,000.00 | $420,000.00 | $420,000.00 |
| Net PPE | $21,000.00 | $27,000.00 | $32,000.00 | $38,000.00 | $38,000.00 |
| Other Non-Current Assets | $2.11M | $2.02M | $360,000.00 | $382,000.00 | $382,000.00 |
| Total Liabilities | $126.35M | $116.94M | $14.72M | $15.11M | $15.11M |
| Total Current Liabilities | $53.08M | $19.32M | $14.72M | $15.11M | $15.11M |
| Payables | $738,000.00 | $1.07M | $1.12M | $2.02M | $2.02M |
| -Accounts Payable | $738,000.00 | $1.07M | $1.12M | $2.02M | $2.02M |
| Current Accrued Expenses | $20.47M | $14.06M | $11.29M | $7.56M | $7.56M |
| Short-Term Debt and Capital Lease Obligation | $25.00M | – | – | – | – |
| -Current Debt | $25.00M | – | – | – | – |
| Total Non-Current Liabilities | $73.27M | $97.62M | $0.00 | $0.00 | $0.00 |
| Long Term Debt and Capital Lease Obligation | $73.27M | – | – | – | – |
| -Long Term Debt | $73.27M | – | – | – | – |
| Total Equity | $503.78M | $550.92M | $638.14M | $646.69M | $646.69M |
| Stockholders' Equity | $503.78M | $550.92M | $638.14M | $646.69M | $646.69M |
| Capital Stock | $9,000.00 | $9,000.00 | $8,000.00 | $8,000.00 | $8,000.00 |
| -Common Stock | $9,000.00 | $9,000.00 | $8,000.00 | $8,000.00 | $8,000.00 |
| Additional Paid-In Capital | $1.30B | $1.29B | $1.13B | $1.10B | $1.10B |
| Retained Earnings | -$794.91M | -$737.58M | -$496.51M | -$457.17M | -$457.17M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$43.10M | -$32.56M | -$39.47M | -$142.42M | -$37.89M |
| Net cash flow from continuing operations | -$43.10M | -$32.56M | -$39.47M | -$142.42M | -$37.89M |
| Net Income from Continuing Operations | -$57.33M | -$241.07M | -$39.34M | -$154.65M | -$32.23M |
| Depreciation & Depletion & Amortization | $6,000.00 | $5,000.00 | $6,000.00 | $59,000.00 | $13,000.00 |
| Other Non-Cash Items | -$4.15M | $195.48M | -$4.63M | -$9.88M | -$4.21M |
| Change in Working Capital | $10.49M | $5.67M | -$2.06M | $2.73M | -$6.74M |
| -Change in Receivables | -$153,000.00 | $47,000.00 | $289,000.00 | -$166,000.00 | -$181,000.00 |
| -Change in Prepaid Assets | $989,000.00 | $1.96M | -$1.95M | $2.47M | $1.57M |
| -Change in Payables and Accrued Expense | $9.66M | $3.67M | -$402,000.00 | $427,000.00 | -$8.13M |
| Net cash flow from investing | $4.70M | -$185.22M | -$44.94M | -$389.75M | -$103.49M |
| Net Cash Flow from Continuing Investing Activities | $4.70M | -$185.22M | -$44.94M | -$389.75M | -$103.49M |
| Net Investment Purchase and Sale | $4.70M | $14.78M | -$44.94M | -$389.74M | -$103.47M |
| Net Other Investing Changes | $0.00 | – | – | – | – |
| Financing Cash Flow | $1.40M | $243.26M | $24.27M | $591.00M | $96.70M |
| Net Cash Flow from Continuing Financing Activities | $1.40M | $243.26M | $24.27M | $591.00M | $96.70M |
| Net Issuance Payments Of Debt | $0.00 | – | – | – | – |
| Net Common Stock Issuance | -$312,000.00 | $143.90M | $20.22M | $578.36M | $91.95M |
| Proceeds from Stock Option Exercised | $2.34M | $2.90M | $4.06M | $13.03M | $5.06M |
| Net Other Financing Charges | -$624,000.00 | -$1.03M | -$1,000.00 | -$391,000.00 | -$305,000.00 |
| Ending Cash Balance | $101.27M | $138.27M | $112.78M | $172.92M | $172.92M |
| Net Change in Cash | -$37.00M | $25.49M | -$60.14M | $58.83M | -$44.68M |
| Beginning Cash Balance | $138.27M | $112.78M | $172.92M | $114.09M | $217.60M |
| Free Cash Flow | -$43.10M | -$32.56M | -$39.47M | -$142.43M | -$37.90M |
| Net PPE Purchase and Sale | – | – | – | -$15,000.00 | -$15,000.00 |
No comments yet — be the first to weigh in on MLYS.
Sign in to join the discussion.